⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNYSE

IQV

IQVIA Holdings Inc.

Healthcare · Diagnostics & Research

256.98USD

-2.2300 (-0.86%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$3.27▲$3.24104
Next quarter$3.65▲$3.6368
Current year$12.97▲$12.81210
Next year$14.46▲$14.19182

Recent quarters

Beat in 4 of the last 4

QuarterEstimateActualSurprise
2026-06-30$3.03$3.15+0.12 (+3.9%)
2026-03-31$2.82$2.9+0.08 (+3.0%)
2025-12-31$3.4$3.42+0.02 (+0.7%)
2025-09-30$2.98$3+0.02 (+0.8%)

Wall Street coverage

251 ratings from 35 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
JP MorganMaintainedOverweight$225 $285Jul 29, 2026
StifelMaintainedBuy$220 $276Jul 29, 2026
TD CowenMaintainedBuy$233 $288Jul 29, 2026
RBC CapitalMaintainedOutperform$221 $247Jul 29, 2026
BMO CapitalMaintainedOutperform$210 $270Jul 29, 2026
BairdMaintainedOutperform$252 $287Jul 29, 2026
MizuhoMaintainedOutperform$215 $230Jul 13, 2026
BairdMaintainedOutperform$230 $249Jul 1, 2026
Morgan StanleyDowngraded from OverweightEqual-Weight$225 $200Jun 17, 2026
Evercore ISI GroupMaintainedOutperform$225 $185Apr 8, 2026
TD CowenUpgraded from HoldBuy$174 $213Mar 9, 2026
BarclaysUpgraded from Equal-WeightOverweight$210Mar 6, 2026
RBC CapitalInitiatedOutperform$221Mar 3, 2026
Truist SecuritiesMaintainedBuy$290 $245Feb 19, 2026
JP MorganMaintainedOverweight$255 $225Feb 6, 2026
CitigroupMaintainedNeutral$230 $200Feb 6, 2026
UBSMaintainedBuy$280 $240Feb 6, 2026
JefferiesMaintainedBuy$270 $255Feb 6, 2026
StifelMaintainedBuy$273 $220Feb 6, 2026
BarclaysMaintainedEqual-Weight$230 $210Feb 6, 2026
TD CowenMaintainedHold$215 $245Jan 22, 2026
Truist SecuritiesMaintainedBuy$265 $290Jan 8, 2026
UBSMaintainedBuy$250 $280Jan 8, 2026
Morgan StanleyMaintainedOverweight$250 $265Dec 2, 2025
BMO CapitalInitiatedOutperform$260Nov 13, 2025

Insider transactions

45 filings from 15 insiders · 6 buy / 6 sell over 6m

Officers and directors of IQV, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
Berkshire James G.Officer, See RemarksExerciseStock Appreciation Right5.4k$131.82$709kSep 2, 2026
Berkshire James G.Officer, See RemarksOther2.7k$261.54$710kSep 2, 2026
Berkshire James G.Officer, See RemarksSell2.7k$261.33$697kSep 2, 2026
Berkshire James G.Officer, See RemarksExercise5.4k$131.82$709kSep 2, 2026
STAUB WALTER. RICHARD IIIOfficerSell5.5k$232.68$1.28MAug 3, 2026
PATEL BHAVIKOfficerSell1.9k$235.27$436kJul 31, 2026
BOUSBIB ARI BChief Executive OfficerExercise156.2k$78.21$12.22MJul 29, 2026
CHEROFSKY KERIANNOfficerSell558$245.21$137kJul 29, 2026
SHERBET ERIC MGeneral CounselSell5.0k$249.16$1.25MJul 29, 2026
BOUSBIB ARI BChief Executive OfficerSell106.3k$244.78$26.09MJul 29, 2026
DANHAKL JOHN GDirectorGrantindirect1.6k——Apr 23, 2026
BURT CAROL JDirectorGrantindirect1.6k——Apr 23, 2026
GOGGINS COLLEEN ADirectorGrant1.6k——Apr 23, 2026
LEONARD JOHN MDirectorGrant1.6k——Apr 23, 2026
CHEROFSKY KERIANNOfficerGrant1.1k——Feb 6, 2026
PATEL BHAVIKOfficerGrant4.1k——Feb 6, 2026
BERKSHIRE JAMES GRANTOfficerGrant2.7k——Feb 6, 2026
HAAS BERNDOfficerGrant8.3k——Feb 6, 2026
FEDOCK MICHAEL J.OfficerGrant6.7k——Feb 6, 2026
GRENFELL ALISTAIROfficerGrant11.8k——Feb 6, 2026

Analyst Notes

Sign in to write

No analyst notes on IQV yet.

Analyst Ratings

18 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current315300Buy2.00
1 mo ago315300Buy2.00
2 mo ago415200Buy1.90
3 mo ago316300Buy2.00
Price target$276.28$240.00 – $300.00
+7.5% to target